Clinical Trial: NCT05879822
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Status:
TERMINATEDPhase:
Phase 2| Lead Sponsor: | Incyte Corporation |
| Information Provided By: | Incyte Corporation |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
Official Title
A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Conditions
Advanced Solid Tumor
Intervention / Treatment
- Drug: INCB099280
Other Study ID Numbers
- INCB 99280-211
- 2022-502716-37-00
Start Date (Actual)
2023-10-30
Primary Completion Date (Actual)
2026-09-30
Study Completion Date (Actual)
2026-09-30
Enrollment (Actual)
73
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Incyte Corporation |
| Information Provided By: | Incyte Corporation |
| Last Update Posted: | 2026-10-20 |
Study Overview
Brief Summary
This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumors.
Official Title
A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
Conditions
Advanced Solid Tumor
Intervention / Treatment
- Drug: INCB099280
Other Study ID Numbers
- INCB 99280-211
- 2022-502716-37-00
Start Date (Actual)
2023-10-30
Primary Completion Date (Actual)
2026-09-30
Study Completion Date (Actual)
2026-09-30
Enrollment (Actual)
73
Study Type
Interventional
Phase
Phase 2